Back
Esperion Therapeutics, Inc. 10K Form
Sell
26
ESPR
Esperion Therapeutics, Inc.
Last Price:
$2.44
Seasonality Move:
-8.92%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
10K form not available
Receive ESPR News And Ratings
See the #1 stock for the next 7 days that we like better than ESPR
ESPR Financial Statistics
Sales & Book Value
| Annual Sales: | $403.1M |
|---|---|
| Cash Flow: | $45.2M |
| Price / Cash Flow: | 0 |
| Annual Sales: | $-1.23 |
| Price / Book: | 0 |
Profitability
| EPS (TTM): | -0.20950 |
|---|---|
| Net Income (TTM): | $-22.7M |
| Gross Margin: | $273.9M |
| Return on Equity: | 0% |
| Return on Assets: | -5.01% |
Esperion Therapeutics, Inc. Earnings Forecast
Key Esperion Therapeutics, Inc. Financial Ratios
-
The Gross Profit Margin over the past 19 years for ESPR is 67.95%.
-
The Selling, General & Administrative Expenses for ESPR have been equal to 0.00% of Gross Profit Margin.
-
The Research & Development expenses have been 11.87% of Revenue.
-
The Net Earning history of ESPR is -5.63% of Total Revenues.
-
Per Share Earnings over the last 19 years have been positive in 8 years.
Esperion Therapeutics, Inc. Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Pharmaceuticals |
| Sector: | Health Care |
| Current Symbol: | ESPR |
| CUSIP: | 29664W |
| Website: | esperion.com |
Debt
| Debt-to-Equity Ratio: | -1.81 |
|---|---|
| Current Ratio: | 1.54 |
| Quick Ratio: | 1.02 |
Price-to-Earnings
| Trailing P/E Ratio: | 0 |
|---|---|
| Forward P/E Ratio: | 8.42 |
ESPR Technical Analysis vs Fundamental Analysis
Sell
26
Esperion Therapeutics, Inc. (ESPR)
is a Sell
Is Esperion Therapeutics, Inc. a Buy or a Sell?
-
Esperion Therapeutics, Inc. stock is rated a SellThe current Esperion Therapeutics, Inc. [ESPR] share price is $2.59. The Score for ESPR is 26, which is 48% below its historic median score of 50, and infers higher risk than normal.